Wegweiser Psoriasis
... Those who become ill can gain help in getting better from understanding the body processes which lead to the illness and information about diagnosis and treatment options. This is particularly true for chronic disorders such as psoriasis, medically called plaque psoriasis. Plaque psoriasis is not co ...
... Those who become ill can gain help in getting better from understanding the body processes which lead to the illness and information about diagnosis and treatment options. This is particularly true for chronic disorders such as psoriasis, medically called plaque psoriasis. Plaque psoriasis is not co ...
Leech Therapeutic Applications
... gastritis, laryngitis) and eye illnesses[3,19]. Some French physicians prescribed leeches for the patient even before seeing him. Actually, the widespread indications of leeching might be attributed to the concept, which suggested that bloodletting by leech was less painful than using the lancet or ...
... gastritis, laryngitis) and eye illnesses[3,19]. Some French physicians prescribed leeches for the patient even before seeing him. Actually, the widespread indications of leeching might be attributed to the concept, which suggested that bloodletting by leech was less painful than using the lancet or ...
What is myotonic dystrophy? - Muscular Dystrophy Australia
... to find the best one to take forward to clinical trial. Scientists have also been searching for other types of molecules that could disrupt the interaction between the toxic RNA and proteins. In 2011 researchers in Spain showed that small pieces of protein which are called ‘peptides’ were effective ...
... to find the best one to take forward to clinical trial. Scientists have also been searching for other types of molecules that could disrupt the interaction between the toxic RNA and proteins. In 2011 researchers in Spain showed that small pieces of protein which are called ‘peptides’ were effective ...
The Therapeutic Relationship in Dialectical Behavior Therapy: A
... treatment, and improvement in symptoms. While some theorists assume that therapeutic alliance is established early in therapy and remains fairly stable across time in treatment, others such as Safran et al. (1990) suggest that the alliance quality fluctuates across time and is likely to be marked by ...
... treatment, and improvement in symptoms. While some theorists assume that therapeutic alliance is established early in therapy and remains fairly stable across time in treatment, others such as Safran et al. (1990) suggest that the alliance quality fluctuates across time and is likely to be marked by ...
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
... Updates to the various sections of the guidelines include the following new information/key changes: ...
... Updates to the various sections of the guidelines include the following new information/key changes: ...
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society
... leukemia or myelodysplastic syndrome who are at high risk for invasive aspergillosis (A-I). Management of breakthrough invasive aspergillosis in the context of mould-active azole prophylaxis is not defined by clinical trial data. The approach to such patients should be individualized on the basis of ...
... leukemia or myelodysplastic syndrome who are at high risk for invasive aspergillosis (A-I). Management of breakthrough invasive aspergillosis in the context of mould-active azole prophylaxis is not defined by clinical trial data. The approach to such patients should be individualized on the basis of ...
Treatment of Aspergillosis
... leukemia or myelodysplastic syndrome who are at high risk for invasive aspergillosis (A-I). Management of breakthrough invasive aspergillosis in the context of mould-active azole prophylaxis is not defined by clinical trial data. The approach to such patients should be individualized on the basis of ...
... leukemia or myelodysplastic syndrome who are at high risk for invasive aspergillosis (A-I). Management of breakthrough invasive aspergillosis in the context of mould-active azole prophylaxis is not defined by clinical trial data. The approach to such patients should be individualized on the basis of ...
Prevention and Treatment of Cancer-Related Infections
... a Categories of risk are based on several factors, including underlying malignancy, whether disease is in remission, duration of neutropenia, prior exposure to chemotherapy, and intensity of immunosuppressive therapy. f See Antiviral Agents (FEV-C) for dosing, spectrum, and specific comments/caution ...
... a Categories of risk are based on several factors, including underlying malignancy, whether disease is in remission, duration of neutropenia, prior exposure to chemotherapy, and intensity of immunosuppressive therapy. f See Antiviral Agents (FEV-C) for dosing, spectrum, and specific comments/caution ...
Anlage 2
... technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage. Complaints are usually nonspecific, such as itching or burning, bleeding, pain, drainage, or a mass. Proper diagnosis requires a high index of suspicion on the part of the surgeon. Innocent ...
... technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage. Complaints are usually nonspecific, such as itching or burning, bleeding, pain, drainage, or a mass. Proper diagnosis requires a high index of suspicion on the part of the surgeon. Innocent ...
Thesis_Lars Brichta_final
... Analysis of SMN2 mRNA levels in peripheral whole blood from patients with type I, II, and III SMA treated with valproic acid................................................. 118 ...
... Analysis of SMN2 mRNA levels in peripheral whole blood from patients with type I, II, and III SMA treated with valproic acid................................................. 118 ...
Leech Therapeutic Applications - Indian Journal of Pharmaceutical
... growth due to its ability to block thrombin‑fibrin binding. Consequently, it was reported that hirudin can reduce DVT, pulmonary embolism and the spread of venous thrombosis[32,36]. Hirudin discovery was the motive for developing many new promising anticoagulants using recombinant technology methods ...
... growth due to its ability to block thrombin‑fibrin binding. Consequently, it was reported that hirudin can reduce DVT, pulmonary embolism and the spread of venous thrombosis[32,36]. Hirudin discovery was the motive for developing many new promising anticoagulants using recombinant technology methods ...
ASFA - INBC
... and enhanced by stringent application of evidence based criteria to ensure consistency within and across fact sheets. The committee-based approach is comprehensive and systematic in assembling objective evidence for disease indications, with strength of recommendation based upon the quality of the e ...
... and enhanced by stringent application of evidence based criteria to ensure consistency within and across fact sheets. The committee-based approach is comprehensive and systematic in assembling objective evidence for disease indications, with strength of recommendation based upon the quality of the e ...
Guidelines on the Use of Therapeutic Apheresis in Clinical
... and enhanced by stringent application of evidence based criteria to ensure consistency within and across fact sheets. The committee-based approach is comprehensive and systematic in assembling objective evidence for disease indications, with strength of recommendation based upon the quality of the e ...
... and enhanced by stringent application of evidence based criteria to ensure consistency within and across fact sheets. The committee-based approach is comprehensive and systematic in assembling objective evidence for disease indications, with strength of recommendation based upon the quality of the e ...
adenomi ipofisari familiari
... FAMILIAL FORMS of PITUITARY ADENOMA FAMILIAL ACROMEGALY Clinical features In more than half of FA families the disease is not transmitted to a succeeding generation by an affected individual, probably because of the early onset of the disorder and the moderately aggressive behavior of the pituitary ...
... FAMILIAL FORMS of PITUITARY ADENOMA FAMILIAL ACROMEGALY Clinical features In more than half of FA families the disease is not transmitted to a succeeding generation by an affected individual, probably because of the early onset of the disorder and the moderately aggressive behavior of the pituitary ...
Diagnosis, Antimicrobial Therapy, and Management of
... or fungemia) plus echocardiographic data (clinically definite). To maintain the high specificity of blood culture results for IE, the Duke criteria required that some patients with high-grade bacteremia with common IE pathogens also fulfill secondary criteria. For example, bacteremia resulting from ...
... or fungemia) plus echocardiographic data (clinically definite). To maintain the high specificity of blood culture results for IE, the Duke criteria required that some patients with high-grade bacteremia with common IE pathogens also fulfill secondary criteria. For example, bacteremia resulting from ...
Hemophilia Overview
... The other, rare form of this condition, acquired hemophilia, results when the body makes specialized proteins called autoantibodies that attack and disable coagulation factor VIII. The production of autoantibodies is sometimes associated with pregnancy, immune system disorders, cancer, or allergic ...
... The other, rare form of this condition, acquired hemophilia, results when the body makes specialized proteins called autoantibodies that attack and disable coagulation factor VIII. The production of autoantibodies is sometimes associated with pregnancy, immune system disorders, cancer, or allergic ...
Prevention and Treatment of Cancer-Related Infections
... k Consider antifungal prophylaxis in all patients with GVHD receiving the clearance of several agents used to treat cancer. n A lipid formulation is generally preferred based on less toxicity. immunosuppressive therapy. Note: All recommendations are category 2A unless otherwise indicated. Clinical T ...
... k Consider antifungal prophylaxis in all patients with GVHD receiving the clearance of several agents used to treat cancer. n A lipid formulation is generally preferred based on less toxicity. immunosuppressive therapy. Note: All recommendations are category 2A unless otherwise indicated. Clinical T ...
Ret/PTC3 is the most frequent form of gene rearrangement
... adult patients and 3 of 10 Japanese children with papillary thyroid carcinomas. In our panel of 40 adult patients, ret/ PTC3 was the most frequent RET rearrangement. This may be due to differences in the etiology of carcinogenesis between childhood and adult cancers. As not only ret/PTC1 but also ot ...
... adult patients and 3 of 10 Japanese children with papillary thyroid carcinomas. In our panel of 40 adult patients, ret/ PTC3 was the most frequent RET rearrangement. This may be due to differences in the etiology of carcinogenesis between childhood and adult cancers. As not only ret/PTC1 but also ot ...
Virulence factors of Salmonella enterica serovar Enteritidis
... humans, the infection can manifest as a non-bloody diarrhea with abdominal pain, nausea, vomiting and fever. The disease (non-typhoidal fever) is usually self-limiting and recovery follows within a few days to a week but, occasionally, systemic infection may occur in vulnerable human patients such a ...
... humans, the infection can manifest as a non-bloody diarrhea with abdominal pain, nausea, vomiting and fever. The disease (non-typhoidal fever) is usually self-limiting and recovery follows within a few days to a week but, occasionally, systemic infection may occur in vulnerable human patients such a ...
Nonsensemediated decay of glutathione peroxidase 1 mRNA in the
... (Moriarty et al., 1998). These ®ndings indicate that halflife studies comparing the consequences of converting the UGA Sec codon to either UAA or UGC will determine whether the NMD of GPx1 mRNA is restricted to newly exported mRNA or characteristic of steady-state mRNA. An intron-less GPx1 gene fail ...
... (Moriarty et al., 1998). These ®ndings indicate that halflife studies comparing the consequences of converting the UGA Sec codon to either UAA or UGC will determine whether the NMD of GPx1 mRNA is restricted to newly exported mRNA or characteristic of steady-state mRNA. An intron-less GPx1 gene fail ...
Pharmacogenomic study of opioid addicts in methadone treatment Francina Fonseca Casals
... studies confirm a wider presence of drug dependence disorders in children of biological parents with alcohol or other substances use disorders even if adopted by non-drug user families. These studies set out three possible theories for transmission, first, the presence of antisocial personality diso ...
... studies confirm a wider presence of drug dependence disorders in children of biological parents with alcohol or other substances use disorders even if adopted by non-drug user families. These studies set out three possible theories for transmission, first, the presence of antisocial personality diso ...
Infective Endocarditis Diagnosis, Antimicrobial Therapy, and
... Class IIb: Usefulness/efficacy is less well established by evidence/opinion. Class III: Conditions for which there is evidence, general agreement, or both that the procedure/treatment is not useful/effective and in some cases may be harmful. ...
... Class IIb: Usefulness/efficacy is less well established by evidence/opinion. Class III: Conditions for which there is evidence, general agreement, or both that the procedure/treatment is not useful/effective and in some cases may be harmful. ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.